Tvardi Therapeutics (Nasdaq: TVRD) Soars on Constructive Part 1 Outcomes for Subsequent-Gen STAT3 Inhibitor TTI-109
Tvardi's next-generation STAT3 inhibitor TTI-109 confirmed fast prodrug conversion, dose-proportional publicity, and improved tolerability versus TTI-101 ...
Read more




